In a patient with impaired renal function requiring hepatitis B treatment, which antiviral is safer: entecavir or tenofovir disoproxil fumarate (or tenofovir alafenamide)?

Entecavir and Tenofovir Alafenamide (TAF) Are Safer Than Tenofovir Disoproxil Fumarate (TDF) in Renal Dysfunction

For treatment-naïve patients with renal dysfunction, both entecavir and tenofovir alafenamide (TAF) are preferred over tenofovir disoproxil fumarate (TDF), with the choice depending on treatment history. 1

Treatment Algorithm Based on Renal Function and Treatment History

For Treatment-Naïve Patients with Renal Dysfunction:

First-line options (in order of preference):

• Tenofovir alafenamide (TAF) - preferred
• Entecavir - equally preferred
• Besifovir (where available) - equally preferred

Avoid: TDF should be avoided in treatment-naïve patients with renal dysfunction 1

For Treatment-Experienced Patients Already on TDF:

Switch to:

• Tenofovir alafenamide (TAF) - preferred option
• Entecavir - acceptable alternative (depending on prior treatment history)

1

Defining Renal Dysfunction for Treatment Selection

Renal dysfunction warranting avoidance of TDF includes any of the following 1:

• eGFR < 60 mL/min/1.73 m²
• Dipstick proteinuria or urine albumin/creatinine ratio > 30 mg/g
• Serum phosphate < 2.5 mg/dL
• Uncontrolled diabetes or hypertension
• Age > 50 years with cardiovascular disease

Evidence Supporting These Recommendations

TAF vs TDF Renal Safety:

Phase 3 trials demonstrated that TDF causes significantly worse renal outcomes than TAF. In patients with risk factors for renal dysfunction, TDF caused a median eGFR decline of -5.0 mL/min compared to only -0.3 mL/min with TAF over 96 weeks 1. When patients switched from TDF to TAF, renal function improved (median eGFR change +0.94 mL/min vs. -2.74 mL/min in those continuing TDF) 1.

Entecavir vs TDF Renal Safety:

The 2018 AASLD guidelines note that existing studies show no significant differences in renal dysfunction between entecavir and TDF in patients without baseline renal impairment 2. However, TDF carries documented risks of acute renal failure, Fanconi syndrome, and hypophosphatemia that are not seen with entecavir 3.

TAF vs Entecavir:

Recent real-world evidence suggests TAF may be more likely to improve renal function compared to entecavir in treatment-experienced patients and special populations, though both are significantly safer than TDF 4. A 2026 study found no significant difference in eGFR decline between TAF and entecavir after switching from TDF (both showed similar renal safety) 5.

Critical Dose Adjustments Required

All nucleos(t)ide analogues require dose adjustment based on creatinine clearance 1:

Contraindications by Creatinine Clearance:

• TAF: Not indicated if CrCl < 15 mL/min without dialysis
• TDF: Not indicated if CrCl < 10 mL/min without dialysis
• Entecavir: Can be used down to CrCl < 10 mL/min with dose adjustment (0.05 mg daily or 0.5 mg weekly)

1, 3

Entecavir Dose Adjustments:

• CrCl ≥ 50: 0.5 mg daily
• CrCl 30-49: 0.25 mg daily or 0.5 mg every 48 hours
• CrCl 10-29: 0.15 mg daily or 0.5 mg every 72 hours
• CrCl < 10: 0.05 mg daily or 0.5 mg weekly

1

Common Pitfalls to Avoid

1. Do not use TDF as first-line therapy in patients with any degree of renal impairment - this is explicitly contraindicated by current guidelines despite TDF being a potent antiviral 1

2. Monitor renal function regularly even with "safer" agents - assess serum creatinine, eGFR, urine glucose, urine protein, and serum phosphorus before initiation and at least annually 2, 3

3. Avoid nephrotoxic co-medications - particularly high-dose or multiple NSAIDs, which can precipitate acute renal failure even in patients stable on antivirals 3

4. TAF has not been studied in decompensated cirrhosis - in this specific population with renal dysfunction, entecavir should be considered over TAF 2

5. Switching from TDF improves but does not fully reverse renal damage - patients who developed renal dysfunction on TDF showed eGFR recovery after switching to TAF or entecavir, but close monitoring remains essential 1, 6

Monitoring Strategy

For patients on any antiviral with renal dysfunction 2, 3:

• Baseline: serum creatinine, eGFR, urine glucose, urine protein, serum phosphorus
• Follow-up: at least annually (more frequently if high-risk or worsening function)
• Persistent bone pain, fractures, or muscle weakness warrant evaluation for proximal renal tubulopathy

The evidence strongly supports avoiding TDF in favor of TAF or entecavir for any patient with existing renal dysfunction or risk factors, with both alternatives showing superior renal safety profiles.